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Despite evidence and consensus across international guidelines
(2) that patients who have experienced an acute exacerbation of
chronic obstructive pulmonary disease (AECOPD) should
participate in pulmonary rehabilitation (PR) within 4 weeks after
hospital discharge, the uptake of this treatment remains low (3).
This is of concern, as PR has been shown to improve dyspnea,
quality of life, and exercise capacity, and reduces hospital
readmissions among patients with AECOPD (2). The authors
rightly indicate that to date, very few studies have investigated the
effects of interventions that aim to increase uptake of PR after an
AECOPD (4). None of the existing published studies used a
randomized controlled trial (RCT) design.
Barker and colleagues conducted an RCT to investigate the
effects of an intervention, an educational video about PR, as an
adjunct to usual care (1). Their primary outcome was uptake of PR
within 28 days of hospital discharge. They concluded that a video
delivered at hospital discharge did not improve uptake of PR.
Although their RCT was well conducted, it does not appear that the
authors applied behavioral theory to guide the key messages included
in the video, nor was there a progressive and systematic framework
guiding the development of their behavior-change intervention as
suggested by the Obesity-related Behavioral Intervention Trials
(ORBIT) model (5). The ORBIT model encourages investigators to
complete a series of studies to define and refine the intervention
(phase I) and to preliminarily test it (phase II) before conducting
efficacy (phase III) and effectiveness (phase IV) trials, akin to the
usual practice of pharmaceutical studies. These suggested steps for
behavioral intervention development ensure that the treatment
package includes essential components offered in an efficient way
and, importantly, helps to ensure a clinically significant effect on the
behavioral risk factor (5). Although this process can be long and
laborious, it is a critical step to prevent a potential waste of
resources—for example, by conducting a large RCT for a treatment
that cannot impact the target clinical outcomes (5).
It seems that Barker and colleagues designed their RCT before
they determined whether their video intervention included the
essential components (e.g., a motivational communication style and
the optimal frequency, duration, and timing of contacts to show the
video). The video was only shown once at hospital discharge, a time
that can be very overwhelming for patients and family members,
and thus is not the best time to make such a decision (6). Indeed, 6
out of the 15 participants interviewed did not recall even watching
the video at hospital discharge. Furthermore, at the outset of the
RCT, the potential effect on behavioral risk factors (such as
knowledge about PR, and self-efficacy/readiness for commencing
PR) was not known, as no preliminary testing of these important
mediate outcomes was performed. Finally, the rationale for their
secondary outcomes is not clear. It is unlikely that an educational
video shown once at hospital discharge would have an impact on
PR completion rates and adherence, physical performance, or
health-related quality of life.
The present study by Barker and colleagues addresses a very
important question and was well conducted for an RCT. However, if
the authors had used a theoretical framework such as the ORBIT
model, they would have had the opportunity to strengthen their
behavioral intervention and make it as effective as possible before
conducting an RCT. It is important to emphasize the value of using a
systematic, phased approach to develop a behavioral treatment
before testing it in rigorous effectiveness trials. n
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From the Authors:
We thank Janaudis-Ferreira and colleagues for their interest in our
randomized controlled trial (1) and their important contribution
to the debate surrounding strategies to improve uptake of
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posthospitalization pulmonary rehabilitation. They make some
salient points and we appreciate the opportunity to respond.
Janaudis-Ferreira and colleagues emphasize the importance of a
progressive and systematic framework to guide the development of
an intervention, citing the Obesity-related Behavioral Intervention
Trials (ORBIT) model developed by the NIH. In particular, they
express concern that we paid insufficient attention to the development
of the intervention before we conducted a randomized controlled trial.
Our team included experienced mixed-methods, qualitative,
and implementation science researchers, as well as a patient and
public involvement group. For details regarding the development
of the intervention, we refer readers to the online supplement of
our work (1). In summary, we used a methodology known as
experience-based codesign (EBCD), which provides a framework
whereby stakeholders (primarily patients and staff) can feel
empowered and work together to improve experiences for patients
and their families, as well as staff.
For those unfamiliar with EBCD, there are parallels to the
ORBIT model and other frameworks for developing complex
interventions. Following our original observation that there were
low referral and uptake rates (2) for posthospitalization pulmonary
rehabilitation even though it is an evidence-based and highly
effective intervention (3), we conducted video-recorded qualitative
interviews with patients hospitalized with acute exacerbation of
chronic obstructive pulmonary disease (COPD) and the hospital
healthcare staff responsible for their care. Patients reported that
little information about pulmonary rehabilitation was provided at
the time of hospital discharge. Members of the healthcare staff
described having limited personal knowledge about and experience
with pulmonary rehabilitation and noted that time pressure was a
barrier to providing information to patients. Clips from these
videos, illustrating the key themes and experiences (known as
“touch-points”), were subsequently combined and edited to
produce a touch-points video. This edited video was then played at
three key stakeholder feedback events: one for patients, one for
healthcare professionals, and one for both patients and healthcare
professionals. The priority that resulted from these stakeholder
events was to develop an education package that would allow
previous patients to tell prospective patients about the benefits of
pulmonary rehabilitation in a visual manner that could be delivered
without significantly affecting staff time. Codesign meetings were
held to develop the intervention (creation and filming of the video)
and to determine how and at which point in the patient pathway it
would be delivered.
A feasibility study was conducted to compare delivery of the
video via tablet computer with delivery of the video via patient
bedside television systems. The latter was not taken forward owing
to patients’ difficulties with accessing the video and the
nonuniversal availability of bedside systems. During the feasibility
study, both patients and staff found the video delivered by the
tablet video to be acceptable and feasible, and we were able to
estimate likely recruitment rates and the feasibility of the outcome
measures. We also refined the delivery of the intervention to keep
researchers blinded to treatment allocation. The development of
the intervention and conduct of the feasibility study occurred
between 2011 and 2015, equivalent to phases 1 and 2 of the ORBIT
methodology. Our recently published randomized controlled trial (1)
is the equivalent of ORBIT phase 3 (conducting an efficacy trial).
Janaudis-Ferreira and colleagues speculate that if we had used
the ORBIT model to develop the intervention, we would have had
the opportunity to strengthen the behavioral component of the
intervention with a view to making it more effective. As we
acknowledged in our paper, there were several reasons why the video
may have not had an adjunctive effect over standard care (delivery
of a COPD discharge bundle), including the lack of an added
counseling element. However, during the EBCD process,
stakeholders (patients and staff) appreciated that a priority for the
intervention was that it should be low cost (with staff time being the
most expensive component of behavioral interventions) and easily
implementable.
We note recent work from the team of Drs. Bourbeau and
Janaudis-Ferreria in which they tested a pulmonary rehabilitation
taster session for patients hospitalized with acute exacerbation
of COPD (4). Although they used the ORBIT methodology, the
intervention they developed was only acceptable to six out of
31 patients (19%) (4). Furthermore, they largely used a quantitative
approach to assess the feasibility, acceptability, and safety of their
intervention. We propose that had Janaudis-Ferreria and colleagues
incorporated a qualitative methodology such as EBCD (which
empowers patients and other stakeholders to codesign an
intervention), they might have produced a more patient-friendly and
feasible intervention that could be evaluated in an efficacy trial. n
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ATS/CDC/ERS/IDSA Clinical Practice Guidelines for
Treatment of Drug-Resistant Tuberculosis: A
Two-edged Sword?
To the Editor:
On the basis of individual patient data (IPD) meta-analysis of
observational studies (1), the World Health Organization released
the consolidated guidelines on drug-resistant tuberculosis
(TB) treatment in 2019 (2). Shortly afterward, using a data
set modified from the aforementioned IPD, the American Thoracic
Society (ATS)/CDC/European Respiratory Society (ERS)/Infectious
Diseases Society of America (IDSA) published their official clinical
practice guidelines for the treatment of drug-resistant TB (3). The
ATS/CDC/ERS/IDSA have recommended the use of linezolid and
bedaquiline to treat all patients with multidrug-resistant TB (MDR-
TB), regardless of the drug-susceptibility testing results. Although
the present guidelines have substantiated the role of linezolid and
bedaquiline in the treatment of fluoroquinolone-resistant MDR-TB,
the IPD meta-analysis findings might have been overextrapolated (4),
with findings regarding the use of linezolid and bedaquiline for the
management of fluoroquinolone-resistant MDR-TB applied to
fluoroquinolone-susceptible MDR-TB. Retrospective analysis of
linezolid in better-defined cohorts with MDR-TB have suggested that
linezolid would be useful largely in the treatment of more complicated
MDR-TB (5). Whether adding bedaquiline to fluoroquinolone would
improve treatment outcomes of fluoroquinolone-susceptible MDR-TB
is still being evaluated in stage 2 of the STREAM (Evaluation of a
Standardised Treatment Regimen of Anti-Tuberculosis Drugs for
Patients with Multidrug-Resistant Tuberculosis) trial. Furthermore,
selection bias and inadequate control of confounding in the IPD meta-
analysis might have yielded some findings that cannot be readily
explained on a biologically plausible basis. Although the
ATS/CDC/ERS/IDSA have explicitly stated that their guidelines were
based on evidence of very low certainty (3), their categorical
recommendation regarding use of linezolid and bedaquiline may pose
a two-edged sword for TB control programs worldwide.
Intuitively, the pros of including linezolid and bedaquiline in a
standard regimen for all types ofMDR-TBmay be greater simplicity for
programmatic implementation and lesser need for drug-susceptibility
testing. However, the major cons probably lie in the concern for patient
safety and tolerance, especially when the standard regimen is
universally applied to many patients with MDR-TB worldwide. The
first global report of surveillance of adverse events in the treatment of
drug-resistant TB has suggested a substantial risk of serious adverse
events related to the use of linezolid and, possibly, bedaquiline (6). The
underlying mechanism, clinical impact, and optimal monitoring of
some potentially serious toxicities, such as those pertaining to the
cardiovascular and neurological systems, are not yet fully understood.
Furthermore, the expertise and resources required for monitoring such
adverse drug reactions likely overwhelm capacity in a large number of
MDR-TB programs with high disease burdens, particularly when
comorbidities such as diabetes mellitus and HIV infection prevail. It
cannot be overemphasized that suboptimal management of drug
toxicities significantly contributes to poor treatment adherence and
eventually contributes to unfavorable treatment outcomes.
Linezolid resistance is nowmounting inmany parts of the world.
Rapid emergence of resistance against bedaquiline would be
formidable for global TB control. Use of linezolid and bedaquiline in
selected patients with MDR-TB may facilitate the optimal use of
resources in a programmatic setting for management of drug adverse
reactions and curtailment of drug resistance.
Directly observed treatment in the holistic patient care package likely
contributed to the high treatment success rates of optimized background
regimens in Trial 213 (7) and in the STREAM trial (8). With advances in
rapid detection of drug resistance, optimized background regimens or
shorter World Health Organization MDR-TB regimens may still have a
place in the programmatic treatment of fluoroquinolone-susceptible
MDR-TB in some parts of the world (8), at least currently. n
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